ND 108E
Alternative Names: HACD-ND108E; ND-108-ELatest Information Update: 07 Jul 2023
At a glance
- Originator Holy Stone Healthcare
- Class Antidementias; Drug conjugates; Glycosaminoglycans
- Mechanism of Action Amyloid beta-protein inhibitors; Mitochondrial protein stimulants; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease